Physician profile
Anil Rama
NPI 1518053131
$14,472.07
in general payments reported to CMS, 2019-2025
25 companies · $6,639 in 2025
The $6,639 reported for 2025 was more than what 90% of Sleep Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $337).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $470 · 2022: $3,055 · 2023: $1,964 · 2024: $2,343 · 2025: $6,639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,757.06 |
| Education | $189.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $2,945.70 | 2023-2025 | Auvelity, Sunosi |
| Jazz Pharmaceuticals INC. | $1,756.98 | 2021-2025 | |
| Harmony Biosciences LLC | $1,542.11 | 2022-2025 | Wakix |
| Avadel Cns Pharmaceuticals, LLC | $1,466.38 | 2024-2025 | Lumryz |
| Acadia Pharmaceuticals INC | $1,422.82 | 2021-2025 | Nuplazid |
| Fisher & Paykel Healthcare INC | $1,072.73 | 2022-2025 | Fisher & Paykel Healthcare |
| Idorsia Pharmaceuticals US INC | $597.08 | 2022-2025 | Quviviq, Quviviq |
| Itamar Medical INC | $509.59 | 2023-2025 | Watchpatone |
| Alkermes, INC. | $443.88 | 2022-2023 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $411.29 | 2022-2023 | Austedo Xr |
| Abbvie INC. | $384.77 | 2022-2025 | |
| Resmed Corp | $377.14 | 2022-2025 | |
| Vertex Pharmaceuticals Incorporated | $326.67 | 2022 | |
| Inspire Medical Systems, INC. | $321.24 | 2024-2025 | Inspire |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $217.59 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $214.08 | 2022-2023 | Fanapt, Hetlioz |
| Eisai INC. | $164.75 | 2021-2022 | |
| Sentynl Therapeutics, INC. | $60.00 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.59 | 2021-2022 | |
| Dexcom, INC. | $48.04 | 2024-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $38.70 | 2025 | Zepbound |
| Noctrix Health, INC. | $38.32 | 2025 | Nidra |
| Otsuka America Pharmaceutical, INC. | $28.76 | 2023 | Rexulti |
| Optinose US, INC. | $18.70 | 2025 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Rama listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.